Outcomes of primary refractory multiple myeloma and the impact of novel therapies. - Wikidata - awgldk - TriplyDB

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

http://www.wikidata.org/entity/Q41543966

about

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Long non-coding RNA CCAT1 promotes multiple myeloma progression by acting as a molecular sponge of miR-181a-5p to modulate HOXA1 expression.Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q36208283-5A3BD3FE-D131-47A2-A4CF-8A542F5721BD Q37108574-3F12D93C-ED15-4DAC-9FF5-5CEBE38C4EBE Q38780843-1608B9B8-92F7-4A0F-9C99-7E78F07044BB Q38817467-48BF2EA6-E41C-474C-B4AC-A26DC6317B0D Q39051838-B52253E0-BA5E-4E48-BC59-E7B3ACC0C5D7 Q40499286-AC306BD6-86C2-4E7A-826B-0DA6A7D540A4 Q41088379-4E7B451C-C2EC-4FFD-BCCF-E0397AB31D73 Q47329036-371B452C-C655-4613-B518-B9E21EE03BE3 Q52699611-E19AF0AA-BBEE-4EB5-8258-B2808229EE65 Q58560605-240079BE-8178-4171-AB92-EC5850F1847D

P2860

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

http://www.wikidata.org/entity/Q41543966

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

@en

type

label

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

@en

prefLabel

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

@en

P1433

Q41543966-35AD4575-5000-47C2-8E61-CFA03D249FCF

P1476

Q41543966-B99E32BB-96F8-417D-A03D-7CB1850F79CB

P2093

Q41543966-07F7CD05-6D62-4B17-BD7B-3FAC649CA1A3

Q41543966-2B9ADFF1-8028-4D58-9A15-1A3922D3BE40

Q41543966-49254FCE-9BE5-4133-B6E4-BB0EBD9DC05D

Q41543966-A93DF60E-3A78-4E17-B05D-09355632D8F2

Q41543966-B30671A4-33B7-4B04-B576-9AB982818AB3

Q41543966-BD12102C-5B12-477C-A98E-F46ABF88E20B

Q41543966-D3DB812B-CBEC-4A67-9B2B-86E317D4AA05

P2860

Q41543966-0803B9FF-AF2F-42E4-B819-8C83A70FADF1

Q41543966-0CF855C2-2F92-4C47-9071-53394B31121A

Q41543966-0EB70F2D-6F10-44E2-A6CA-42F84217DBBF

Q41543966-1EF11D48-5C15-4EFD-8055-794AC7319978

Q41543966-2EE9B695-E7D6-432B-8622-D1E5671AA1A9

Q41543966-3F32DCA0-46C3-4B4C-BA08-6DB0B04048E0

Q41543966-41E6E8E4-435C-4292-9BDF-06279FF20B1C

Q41543966-46285DDE-4C0D-4420-9033-8CA8458D4E50

Q41543966-49D24347-7468-4B27-967C-D8B12764873B

Q41543966-585F6039-ED31-4F15-81C3-F92E9302C7C9

P304

Q41543966-5379D44B-4DEF-4924-8ABE-6B68F5FE0816

P31

Q41543966-4BFCF87F-19E9-4AA7-BCED-FB03ACF7F711

P356

Q41543966-0F4B5383-9A0C-494C-826C-936FFB946EDB

P433

Q41543966-2A6840FA-59E1-446B-8193-60E6D7BB3EBB

P478

Q41543966-D6EAFF3A-0245-4DE2-B15C-0BD0BF38BAC9

P50

Q41543966-23D9A6A9-0AD6-44F0-8852-EE4B71CD1C13

Q41543966-298F80C5-24CF-4701-A798-D704D11B5D4F

Q41543966-2B7C7620-C82B-42B2-AC87-E14B5C02C2C3

Q41543966-4010F77E-0140-42A6-B0AC-22B3CF6E8C80

Q41543966-6E5EA0ED-2B41-4E78-A5E5-D9992E60F372

Q41543966-76BC7B6E-E031-473D-93C6-A6BA79BFD03E

Q41543966-7E60EBE9-C228-42C2-BD7C-998B72070D21

Q41543966-C997FBE7-F242-40B4-B50C-19A5A0A4745E

P577

Q41543966-D5E9C137-DE31-4AB5-868F-BAB91218A999

P698

Q41543966-9743A785-F789-45F0-BE06-20F56C2B07F2

P932

Q41543966-9AF3DA28-1675-4C98-A3F9-9A43451B2EAB

P356

P1433

American Journal of Hematology

P1476

Outcomes of primary refractory multiple myeloma and the impact of novel therapies.

@en

P2093

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Lisa Hwa

http://www.w3.org/2001/XMLSchema#string

Neil Majithia

http://www.w3.org/2001/XMLSchema#string

Prashant Kapoor

http://www.w3.org/2001/XMLSchema#string

Ronald S Go

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Nonparametric Estimation from Incomplete Observations

Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.

Antitumor activity of thalidomide in refractory multiple myeloma.

Integrin-mediated drug resistance in multiple myeloma.

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.

P304

981-985

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24131

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

Suzanne R Hayman

P577

2015-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26214732

http://www.w3.org/2001/XMLSchema#string

P932

5801545

http://www.w3.org/2001/XMLSchema#string